https://www.drugtargetreview.com/metabolic-vulnerabilities-identified-in-rare-fibrolamellar-liver-cancer/2135588.article Drug Target Review en 2026-05-29T12:00:00+01:00 Metabolic vulnerabilities identified in rare Fibrolamellar liver cancer Assays,Oncology,Analytical Techniques,Drug Targets,Mass Spectrometry,Metabolomics,Metabolic disorders,Rare & Genetic Disorders,Disease Research,Precision Medicine https://www.drugtargetreview.com/ginkgo-bioworks-launches-adme-one-platform-for-early-stage-screening/2135583.article Drug Target Review en 2026-05-29T09:48:00+01:00 Ginkgo Bioworks launches ADME-One platform for early-stage screening Drug Discovery,High-Throughput Screening (HTS),Lab Tools & Automation,Drug Discovery Processes,Companies,Hit-to-Lead,Artificial Intelligence (AI),Bioinformatics,Small Molecules https://www.drugtargetreview.com/ai-platform-identifies-novel-gp130-inhibitor-for-colorectal-cancer/2135569.article Drug Target Review en 2026-05-28T12:00:00+01:00 AI platform identifies novel gp130 inhibitor for colorectal cancer Drug Discovery,Oncology,Drug Discovery Processes,Drug Targets,Drug Leads,Medicinal Chemistry,Artificial Intelligence (AI),Bioinformatics,Machine Learning (ML) https://www.drugtargetreview.com/ai-identifies-23-antiviral-candidates-for-bundibugyo-ebola-strain/2135568.article Drug Target Review en 2026-05-28T09:00:00+01:00 AI identifies 23 antiviral candidates for Bundibugyo Ebola strain Drug Discovery,Molecular Modelling,Drug Development,Artificial Intelligence (AI),Antimicrobials,Bioinformatics,Public Health & Safety,Infectious disease,Machine Learning (ML)